Griffin Simon J, Simmons Rebecca K, Prevost A Toby, Williams Kate M, Hardeman Wendy, Sutton Stephen, Brage Søren, Ekelund Ulf, Parker Richard A, Wareham Nicholas J, Kinmonth Ann Louise
MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Cambridge, UK,
Diabetologia. 2014 Jul;57(7):1308-19. doi: 10.1007/s00125-014-3236-6. Epub 2014 Apr 24.
AIMS/HYPOTHESIS: The aim of this study was to assess whether or not a theory-based behaviour change intervention delivered by trained and quality-assured lifestyle facilitators can achieve and maintain improvements in physical activity, dietary change, medication adherence and smoking cessation in people with recently diagnosed type 2 diabetes.
An explanatory randomised controlled trial was conducted in 34 general practices in Eastern England (Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen Detected Diabetes in Primary Care-Plus [ADDITION-Plus]). In all, 478 patients meeting eligibility criteria (age 40 to 69 years with recently diagnosed screen or clinically detected diabetes) were individually randomised to receive either intensive treatment (n = 239) or intensive treatment plus a theory-based behaviour change intervention led by a facilitator external to the general practice team (n = 239). Randomisation was central and independent using a partial minimisation procedure to balance stratifiers between treatment arms. Facilitators taught patients skills to facilitate change in and maintenance of key health behaviours, including goal setting, self-monitoring and building habits. Primary outcomes included physical activity energy expenditure (individually calibrated heart rate monitoring and movement sensing), change in objectively measured fruit and vegetable intake (plasma vitamin C), medication adherence (plasma drug levels) and smoking status (plasma cotinine levels) at 1 year. Measurements, data entry and laboratory analysis were conducted with staff unaware of participants' study group allocation.
Of 475 participants still alive, 444 (93%; intervention group 95%, comparison group 92%) attended 1-year follow-up. There were no significant differences between groups in physical activity (difference: +1.50 kJ kg(-1) day(-1); 95% CI -1.74, 4.74), plasma vitamin C (difference: -3.84 μmol/l; 95% CI -8.07, 0.38), smoking (OR 1.37; 95% CI 0.77, 2.43) and plasma drug levels (difference in metformin levels: -119.5 μmol/l; 95% CI -335.0, 95.9). Cardiovascular risk factors and self-reported behaviour improved in both groups with no significant differences between groups.
CONCLUSIONS/INTERPRETATION: For patients with recently diagnosed type 2 diabetes receiving intensive treatment in UK primary care, a facilitator-led individually tailored behaviour change intervention did not improve objectively measured health behaviours or cardiovascular risk factors over 1 year.
ISRCTN99175498 FUNDING: The trial is supported by the Medical Research Council, the Wellcome Trust, National Health Service R&D support funding (including the Primary Care Research and Diabetes Research Networks) and National Institute of Health Research under its Programme Grants for Applied Research scheme. The Primary Care Unit is supported by NIHR Research funds. Bio-Rad provided equipment for HbA1c testing during the screening phase.
目的/假设:本研究旨在评估由经过培训且质量有保障的生活方式促进者实施的基于理论的行为改变干预措施,能否使新诊断的2型糖尿病患者在身体活动、饮食改变、药物依从性和戒烟方面取得并维持改善。
在英格兰东部的34家全科诊所进行了一项解释性随机对照试验(初级保健中筛查发现糖尿病患者强化治疗的英 - 丹麦 - 荷兰研究 - 加项[ADDITION - Plus])。共有478名符合入选标准的患者(年龄40至69岁,新诊断为筛查或临床检测出糖尿病)被单独随机分组,分别接受强化治疗(n = 239)或强化治疗加由全科医疗团队外部的促进者主导的基于理论的行为改变干预(n = 239)。随机分组通过中央独立的部分最小化程序进行,以平衡各治疗组之间的分层因素。促进者向患者传授促进关键健康行为改变和维持的技能,包括目标设定、自我监测和习惯养成。主要结局包括1年后的身体活动能量消耗(个体校准心率监测和运动传感)、客观测量的水果和蔬菜摄入量变化(血浆维生素C)、药物依从性(血浆药物水平)和吸烟状况(血浆可替宁水平)。测量、数据录入和实验室分析由对参与者的研究组分配不知情的工作人员进行。
在475名仍存活的参与者中,444名(93%;干预组95%,对照组92%)参加了1年随访。两组在身体活动(差异:+1.50 kJ·kg⁻¹·天⁻¹;95%置信区间 -1.74,4.74)、血浆维生素C(差异:-3.84 μmol/l;95%置信区间 -8.07,0.38)、吸烟(比值比1.37;95%置信区间0.77,2.43)和血浆药物水平(二甲双胍水平差异:-119.5 μmol/l;95%置信区间 -335.0,95.9)方面无显著差异。两组的心血管危险因素和自我报告行为均有所改善,但组间无显著差异。
结论/解读:对于在英国初级保健中接受强化治疗的新诊断2型糖尿病患者,由促进者主导的个体化行为改变干预在1年内并未改善客观测量的健康行为或心血管危险因素。
ISRCTN99175498 资助:该试验由医学研究理事会、惠康信托基金会、国民健康服务研发支持基金(包括初级保健研究和糖尿病研究网络)以及美国国立卫生研究院根据其应用研究计划资助项目提供支持。初级保健单位由NIHR研究基金提供支持。Bio - Rad在筛查阶段提供了糖化血红蛋白检测设备。